Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2024 15:04 ET | Source: Alation, Inc.

Alation Deepens Integration with Snowflake to Improve Data Quality and Deliver AI-Ready Data

REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Alation Inc., the data intelligence company, today announced at Snowflake’s annual user conference, Snowflake Data Cloud Summit 2024, a...
June 04, 2024 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Set to Join Russell 3000® Index

REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
May 23, 2024 09:04 ET | Source: Alation, Inc.

Alation Earns FedRAMP “In Process” Status to Deliver Data Intelligence to the Federal Government

REDWOOD CITY, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Alation Inc., the data intelligence company, today announced its achievement of the Federal Risk and Authorization Management Program...
May 22, 2024 09:06 ET | Source: Alation, Inc.

Alation Signs Reseller Agreement with NTT DATA to Expand its Presence in Japan and Meet Surging Demand for Data Intelligence

REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Alation, Inc., the data intelligence company, today announced the expansion of its global operations in Japan. Alation partnered with NTT DATA,...
May 09, 2024 16:01 ET | Source: eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway...
May 08, 2024 16:00 ET | Source: Cytokinetics, Incorporated

Cytokinetics Reports First Quarter 2024 Financial Results

Primary Results and Two Additional Analyses from SEQUOIA-HCM to be Presented in a Late-Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress Opened...
May 07, 2024 16:05 ET | Source: PubMatic, Inc.

PubMatic Announces Record First Quarter 2024 Financial Results

PubMatic Announces Record First Quarter 2024 Financial Results
May 07, 2024 07:00 ET | Source: Zenas BioPharma

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

Financing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital, and other new and existing investors Proceeds to...
March 25, 2024 16:01 ET | Source: eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024 Median progression free...
March 18, 2024 16:05 ET | Source: Adverum Biotechnologies, Inc.

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - -...